



Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Gabor Butora, et al . Art Unit:  
Serial No. : 10/533,326 Case No.: 21036YP . 1625  
Filed : May 2, 2005 . Examiner:  
For : TETRAHYDROPYRANYL CYCLOPENTYL . Solola,  
BENZYLAMIDE MODULATORS OF CHEMOKINE . Taofiq A.  
RECEPTOR ACTIVITY .

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. This is supplemental to an Information Disclosure Statement that was filed on December 28, 2005. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE  
DATE OF DEPOSIT 8-17-2007  
EXPRESS MAIL NO. EV83580824548  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"  
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO  
COMMISSIONER FOR PATENTS, P.O. BOX 1450,  
ALEXANDRIA, VIRGINIA 22313-1450.  
MAILED BY Heather Anne Moore  
DATE 8/17/07


This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed before issuance of a First Office Action. No fee is believed to be due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 

James L. McGinnis  
Reg. No. 34,387  
Attorney for Applicants

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0641

Date: August 17, 2007

## STATEMENT BY APPLICANTS

(use as many sheets as necessary)

Sheet

1

of

**COMPLETE IF KNOWN****Application Number**

10/533,326

**Filing Date**

May 2, 2005

**First Named Inventor**

Gabor Butora, et al.

Group Art Unit

1625

Examiner Name

Taofiq A. Solola

Attorney Docket Number

21036YP

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.)

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007